QHSLab repurchases $470K promissory note with 1.57M shares, extinguishing related-party debt

QHSLab, Inc.

Repurchased and cancelled promissory note held by MedScience; outstanding principal and interest $470,529 as of Dec 31, 2025.
Issued 1,568,432 shares of common stock as consideration; shares issued in private transaction exempt from registration.
CEO Troy Grogan is minority shareholder of MedScience; received no personal distribution from transaction.
Company states repurchase simplifies capital structure and eliminates related-party debt obligation.

item 1.01 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

QHSLab, Inc. terminated Repurchase Agreement with MedScience Research Group, Inc..

Action: termination
Counterparty: MedScience Research Group, Inc.

Exact text from the filing

QHSLab, Inc. (the “Company”) consummated a Note Repurchase Agreement (the “Repurchase Agreement”) with MedScience Research Group, Inc., a Florida corporation (“MedScience”).

View on SEC.gov

336 material agreements filed in the last 30 days. Browse all material agreements →

QHSLab, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-003438

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.